Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.78 |
| ▸ | CA2 | P00918 | 5/20 | 0.78 |
| ▸ | CA9 | Q16790 | 5/20 | 0.78 |
| ▸ | CA12 | O43570 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | GUSB | P08236 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15325008 | 0.88 | CA1 (1.00) | CA1CA2CA9CA12LMNA | |
| SCHEMBL9232636 | 0.83 | CA1 (0.70) | CA1CA2CA9CA12LMNA | |
| SCHEMBL13849447 | 0.82 | CA1 (0.68) | CA1CA2CA9CA12LMNA | |
| SCHEMBL9232639 | 0.82 | CA1 (0.68) | CA1CA2CA9CA12LMNA | |
| SCHEMBL11826091 | 0.82 | CA1 (0.55) | CA1CA2CA9CA12LMNA | |
| SCHEMBL9232630 | 0.81 | CA1 (0.67) | CA1CA2CA9CA12LMNA | |
| SCHEMBL11581585 | 0.81 | CA1 (0.76) | CA1CA2CA9CA12LMNA | |
| SCHEMBL11834463 | 0.80 | CA1 (0.53) | CA1CA2CA9CA12LMNA | |
| SCHEMBL31018735 | 0.80 | CA1 (0.65) | CA1CA2CA9CA12LMNA | |
| SCHEMBL11579155 | 0.80 | LMNA (0.89) | CA1CA2CA9CA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3010345-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | The Regents of The University of California (US) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014205414-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014205414-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20130096123-A1 | RADIATION SENSITISER COMPOSITIONS | EUPHARMA PTY LTD (AU) | 2013-04-18 | — | — | US | disclosed |
| EP-2558090-A1 | RADIATION SENSITISER COMPOSITIONS | Eupharma Pty Ltd (AU) | 2013-02-20 | — | — | EP | disclosed |
| EP-2495563-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | Fujifilm RI Pharma Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| CN-101486707-A | 2-methyl-5-nitro glyoxaline compound, preparation and use thereof | UNIV BEIJING NORMAL (CN) | 2009-07-22 | — | — | CN | disclosed |
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | ALTANA PHARMA AG (DE) | 2004-08-12 | — | — | US | disclosed |
| EP-1395592-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA Pharma AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| EP-0921122-B1 | EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002094831-A1 | NOVEL PYRIDYLMETHYLAMINOPYRIMIDINES | ALTANA PHARMA AG (DE) | 2002-11-28 | — | — | WO | disclosed |
| US-6110967-A | USEFUL AS AGENTS FOR PREVENTING AND TREATING METABOLIC OSTEOPATHY SUCH AS OSTEOPOROSIS, HYPERCALCEMIA AND BONE METASTASIS OF CANCER BECAUSE THEY SPECIFICALLY INHIBITS CATHEPSIN L AND ITS FAMILY ENZYMES TO INHIBIT BONE RESORPTION | TAIHO PHARMACEUTICALS CO., LTD. (JP) | 2000-08-29 | — | — | US | disclosed |
| EP-0921122-A1 | NOVEL EPOXYSUCCINAMIDE DERIVATIVES OR SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-4193979-A | Sodium 3-[[[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]-amino]carbonyl]-2-pyridinecarboxylic acid and related compounds labeled with technetium-99m | G. D. SEARLE & CO. (US) | 1980-03-18 | — | — | US | disclosed |
| US-3997572-A | N-[2-(nitro-1-imidazolyl)ethyl]naphthal imides | G. D. SEARLE & CO. (US) | 1976-12-14 | — | — | US | disclosed |
| US-3962274-A | 1-AZIDOALKYLIMIDAZOLES | G. D. SEARLE & CO. (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | CA1 4847/4885CA2 4271/4885CA9 4167/4885 |
| US-20040158066-A1 | Novel pyridylmethylaminopyrimidines | PGLS, PLPBP, PDXK | CA1 4818/4885CA2 4569/4885CA9 4411/4885 |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | NISCH, CNDP2, MYADM | CA1 3891/4885CA2 2962/4885CA9 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.